Today: 20 May 2026
BMNR stock rises as MSCI backs off crypto‑treasury index shakeup; BitMine vote looms
8 January 2026
2 mins read

BMNR stock rises as MSCI backs off crypto‑treasury index shakeup; BitMine vote looms

New York, Jan 8, 2026, 14:48 (EST) — Regular session

  • BMNR shares rose about 3% in afternoon trade as investors digested MSCI’s latest stance on crypto‑treasury firms.
  • MSCI said it would not move ahead, for now, with an exclusion plan tied to February’s index review.
  • BitMine’s shareholder vote on a major authorized-share increase is due next week.

Shares of BitMine Immersion Technologies, Inc. (BMNR) were up 3.1% at $31.30 in afternoon trading on Thursday, after swinging between $29.20 and $31.66. The move comes after MSCI dropped a plan to exclude so‑called digital‑asset treasury firms from its indexes.

Crypto‑treasury firms — often called digital asset treasury companies, or DATCOs — have become a traded proxy for bitcoin and ether, the token used on the ethereum network, and index eligibility can matter because passive funds track those benchmarks. Owen Lau at Clear Street said MSCI’s move “removes a material near-term technical risk,” but JonesTrading’s Mike O’Rourke said “exclusion is postponed until later in the year.” Lau added the “most likely middle ground” is MSCI will “grandfather existing DATCOs already in the Indexes.” Reuters

MSCI said it will not implement its proposal to exclude digital asset treasury companies from the MSCI Global Investable Market Indexes as part of the February 2026 index review, and plans a broader consultation on how it treats non-operating companies. It also said it will not increase the share-count and inclusion factors it uses in index weightings — its “NOS,” “FIF” and “DIF” — and will defer additions or size-segment changes for securities on its preliminary list. MSCI

BitMine appears on MSCI’s preliminary list of potentially impacted securities — companies flagged because digital-asset holdings were assessed at 50% or more of total assets — alongside names such as Strategy, MARA Holdings and Riot Platforms. The list, based on data as of late 2025, labeled BitMine as a non-constituent in MSCI’s All Cap universe at the time.

Trading in these names has stayed choppy. Stocktwits reported BitMine shares jumped 2.3% in after-hours trade on Tuesday after MSCI’s update, alongside gains in other crypto‑treasury stocks.

Bitcoin was down about 0.14% at around $91,001 on Thursday, while ether fell roughly 1% to about $3,114. Those moves often set the tone for BitMine and other crypto‑linked equities, even when the catalyst starts as an index-policy headline.

A separate, closer catalyst sits on BitMine’s calendar. In a Jan. 2 filing, the company urged shareholders to approve a charter change at its Jan. 15 annual meeting that would lift authorized shares — the ceiling on stock it can issue — to 50 billion from 500 million; the proxy deadline is Jan. 14. Chairman Tom Lee said the change “would enable the Company to implement future stock splits as needed.” SEC

But the setup cuts both ways. BitMine describes itself as a bitcoin-and-ether network company focused on accumulating crypto, so a sharp pullback in token prices can hit both its balance sheet and the stock, while MSCI’s broader review keeps questions around index treatment alive.

What traders watch next: any further MSCI guidance as it prepares that broader consultation and moves toward the February review, plus BitMine’s Jan. 14 proxy deadline and Jan. 15 meeting. The company’s next earnings report is scheduled for Jan. 28.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking
Previous Story

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Sandisk (SNDK) stock drops after CES-fueled surge cools, with earnings next
Next Story

Sandisk (SNDK) stock drops after CES-fueled surge cools, with earnings next

Go toTop